Skip to main content

Table 3 Characteristics of patients with BM-CR

From: Histomorphological responses after therapy with pegylated interferon α-2a in patients with essential thrombocythemia (ET) and polycythemia vera (PV)

Pt Pts DG DX_ time to enroll., mos HR DUR, mos Mol. status DUR of therapy, mos Initial BMb Best BM resp.—time from enroll., mos Last BM Resp. DUR, mos
1a 59 M PV 97 79.7* PMR 15.3 MF 2, 90%, OST MF 0, NEG morph. and OST, 40%—43 MF 1, NEG morph., 60% 30
2a 75 F PV 119 89.4 CMR 91.4 MF 2, 80% MF 0, NEG morph., 50%—48 MF 1, NEG morph., 50% 48
3a 38 M PV 1 100.9 CMR 100.9 MF 2, 90%, OST MF 1, NEG morph. and OST, 30%—56 MF 1, NEG morph and OST., 50% 40
4 58 M PV 35 87.1* CMR 99.0 MF 2, 90%, OST MF 0, NEG morph. and OST, 30%—69 MF 1, POS morph., 60% 48
5 37 F PV 5 94.8 CMR 94.8 MF 1, 70%, OST MF 0, NEG morph., 40%—60 MF 1, NEG morph., 40%, + OST 48
6a 44 M PV 3 74.7* CMR 98.3 MF 1, 70% MF 0, NEG morph., 30%—48 MF 1, NEG morph., 50% 36
7 46 M PV 350 79.5 PMR 79.5 MF 1, 60% MF 0, NEG morph., 40%—48 MF 1, POS morph., 50% 30
8a 47 F ET 33 83.0 CMR 83.0 MF 1, 50% MF 1, NEG morph., 20%—60 MF 0, NEG morph., 30% 24
9a 35 M ET 14 79.8 CMR 30.4 MF 1, 50% MF 0, NEG morph., 30%—30 MF 0, NEG morph., 50% 52
10a 53 F ET 43 91.7 NR 58.7 MF 1, 50% MF 0, NEG morph., 40%—48 MF 0, NEG morph., 20% 24
11a 39 F ET 2 92.6 TN 18.1 MF 1, 50% MF 0, NEG morph., 40%—66 MF 0, NEG morph., 40% 24
12a 23 F ET 30 100.8 TN 91.5 MF 1, 20% MF 1, NEG morph., 30%—60 MF 0, NEG morph., 30% 24
13 73 F ET 110 59.3* PMR 30.4 MF 2, 60%, OST MF 1, NEG morph., 30%—30 MF 1, POS morph., 40% 24
  1. DUR duration, DX diagnosis, OST osteosclerosis, Resp response, morph. morphology, enroll. enrollment to study, NEG negative, POS positive
  2. aPatients who sustained a BM response at last follow-up, * lost HR
  3. bBM description includes degree of reticulin fibrosis on scale of 0–3, % BM cellularity, and presence of osteosclerosis (OST)